REGNRegeneron PharmaceuticalsSigning up patients
A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)
Relapsed/Refractory Systemic Light Chain Amyloidosis
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 1/2
- Patients
- 220 (planned)
- Started
- Aug 7, 2024
- Main results expected
- Aug 20, 2028
- Fully finished
- Feb 20, 2035
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of dose-limiting toxicity (DLTs)
Measured over: Up to 28 Days
Achievement of hematologic complete response (CR) as determined by the Independent Review Committee (IRC)
Measured over: Up to 3 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06292780 · record last updated 2026-08-18 · checked 2026-11-09 15:47 UTC